Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Why do people get headaches and migraines? A child neurologist explains the science of head pain and how to treat it - 2What to watch for in weight loss drugs in 2026
- 35 VIP Voice Exhibitions in Energized Movies
- 4Flu cases spiking this holiday season, CDC data shows
- 5Doctors looking into hormone therapy as a way to ward off dementia in women
- 'Euphoria' Season 3 trailer includes Eric Dane's final appearance, Jacob Elordi and Sydney Sweeney at the altar and Rue's 'Breaking Bad' era
- Ober Gabelhorn glacier reveals remains of man missing for over three decades
- Taylor Swift's 'The End of an Era' docuseries: Everything you need to know, plus how to watch for less
- The most effective method to Guarantee Simple Availability in Seniors' SUVs
- Plans for ‘stop anywhere’ night buses recommended by government for women’s safety
- Tech for Wellbeing: Applications and Devices for a Better You
- Party Urban areas of the World
- Israel Police decry online defamation campaign against female officer in Jerusalem
- Instructions to Keep up with Your Traded Teeth for Life span
